Alterity Therapeutics (ATHE) Shares Outstanding (Weighted Average) (2015 - 2025)
Alterity Therapeutics' quarterly Shares Outstanding (Weighted Average) came in at $185491.4 billion in Q4 2025, up 26.9% year-on-year from $146172.1 billion in Q4 2024, and up 10.15% quarter-over-quarter from $168401.6 billion in Q2 2025.
Alterity Therapeutics has reported Shares Outstanding (Weighted Average) for 11 years, with the latest figure at $185491.4 billion in Q4 2025.
- For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 26.9% year-over-year to $185491.4 billion; the trailing twelve-month figure through Dec 2025 stood at $185491.4 billion (up 26.9% YoY), and the FY2025 full-year result was $168401.6 billion, up 114509494.13% from the prior year.
- Shares Outstanding (Weighted Average) for Q4 2025 stood at $185491.4 billion, up from $168401.6 billion in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $185491.4 billion in Q4 2025, with the low at $147.1 million in Q2 2024.
- Average Shares Outstanding (Weighted Average) over 5 years is $93626.8 billion, with a median of $140218.3 billion recorded in 2022.
- Year-over-year, Shares Outstanding (Weighted Average) plunged 93.13% in 2024 and soared 114509494.13% in 2025.
- Tracing ATHE's Shares Outstanding (Weighted Average) over 5 years: stood at $155764.2 billion in 2021, then declined by 9.81% to $140489.0 billion in 2022, then declined by 0.39% to $139947.6 billion in 2023, then climbed by 4.45% to $146172.1 billion in 2024, then advanced by 26.9% to $185491.4 billion in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $185491.4 billion (Q4 2025), $168401.6 billion (Q2 2025), and $146172.1 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 198.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 185,491.37 Bn |
| Jun 30, 2025 | 168,401.57 Bn |
| Dec 31, 2024 | 146,172.09 Bn |
| Jun 30, 2024 | 3.46 Bn |
| Dec 31, 2023 | 139,947.63 Bn |
| Jun 30, 2023 | 2.14 Bn |
| Dec 31, 2022 | 140,488.96 Bn |
| Jun 30, 2022 | 153.13 Mn |
| Dec 31, 2021 | 155,764.22 Bn |
| Jun 30, 2021 | 1.60 Bn |
| Dec 31, 2020 | 142,454.29 Bn |
| Jun 30, 2020 | 679.91 Mn |
| Dec 31, 2019 | 444,072.78 |
| Jun 30, 2019 | 602.99 Mn |
| Dec 31, 2018 | 1.11 Mn |
| Jun 30, 2018 | 404.18 Mn |
| Dec 31, 2017 | 522,946.22 |
| Jun 30, 2017 | 401.06 Mn |
| Dec 31, 2016 | 1.09 Mn |
| Jun 30, 2016 | 2.02 Mn |
| Dec 31, 2015 | 105,707.52 Bn |
| Jun 30, 2015 | 14.00 Mn |